Navigation Links
New ISHLT nomenclature & diagnostic criteria: Antibody-mediated rejection in heart transplantation
Date:11/17/2013

New York, NY, November 18, 2013 Antibody-mediated rejection of the transplanted heart is a recognized clinical complication and a major limitation to survival of patients who have undergone heart transplantation. Experts have now developed a new working formulation for the pathologic diagnosis, grading, and reporting of cardiac antibody-mediated rejection. Their consensus statement is published in the December issue of The Journal of Heart and Lung Transplantation and is freely available at http://www.jhltonline.org.

Heart transplantation is the definitive therapy for eligible patients with end-stage heart failure. However, antibody-mediated rejection (AMR) of a cardiac allograft -- a heart from a genetically non-identical donor is a recognized clinical complication in the management of heart transplant patients and can develop more than a year after transplantation has occurred.

Over the past 25 years experts have wrestled to establish practical working definitions to guide the diagnosis, grading, and reporting of AMR. In the initial 1990 International Society for Heart Transplantation (ISHLT) working formulation, "positive immunofluorescence, vasculitis, or severe edema in the absence of cellular infiltrates" were proposed as the key diagnostic hallmarks. This working formulation included the qualified recommendation that "centers routinely performing immunofluorescence should consider staining all endomyocardial biopsy specimens obtained in the first six weeks following transplantation." More detailed histopathologic features and immunopathologic criteria were proposed in the follow-up 2005 ISHLT revision of nomenclature and diagnostic criteria.

In 2010 the increasing awareness of asymptomatic AMR and its association with accelerated cardiac allograft vasculopathy and increased mortality, together with the need to define a therapeutic strategy, led an international multidisciplinary group to recommend the removal of the clinical and serologic components specified in the 2005 working formulation as requirements for the diagnosis of AMR. The biopsy tissue diagnosis of cardiac AMR has since been established by using agreed reproducible histopathologic and immunopathologic criteria akin to the diagnosis of acute cellular rejection (ACR).

In this statement, members of the Pathology Council of ISHLT led by Gerald J. Berry, MD, Professor of Pathology, Stanford University School of Medicine, and Director, Cardiac and Pulmonary Pathology, Stanford University Hospital and Clinics and Lucile Packard Children's Hospital at Stanford, reports the consensus findings from a series of meetings held between 2010 and 2012 to develop a new working formulation for the pathologic diagnosis, grading, and reporting of cardiac AMR.

"Tremendous progress has been achieved over the last decade in recognizing, diagnosing and grading AMR, but its recognition and diagnosis by histopathology, even among experienced transplant pathologists, is challenging," says Berry. "With the rapid changes that occur in medicine, new and more specific antibodiesor even new technologiesmay provide more accurate and reproducible results for the diagnosis of AMR. Until then, there remain numerous challenges and unresolved clinical, immunologic, and pathologic questions. It is our distinct intention and hope that the diagnostic criteria and grading scheme presented in this working formulation will aid in the resolution of these and other issues."

The report covers:

  • Histopathologic features of AMR
  • Interstitial edema
  • Hemorrhage, necrosis, and vascular thrombosis
  • Immunopathologic findings in cardiac AMR
  • Antibody panels for paraffin immunohistochemistry
  • Antibody panels for frozen-tissue immunofluorescence
  • Summary of the ISHLT 2012 pAMR biopsy specimen validation study
  • Pathologic grading and reporting of cardiac AMR
  • Indications, frequency, and follow-up of immunostaining
  • Initial and surveillance immunophenotypic studies
  • Follow-up of immunophenotypic studies after a positive result
  • Surveillance and immunostaining for late-onset AMR
  • Mixed ACR and AMR

The Working Group points out that this document reflects the current state of knowledge and experience of transplant pathologists, and also serves as a framework for the organization of future multicenter studies. Areas pinpointed as needing further evaluation include AMR in children and the threshold for therapeutic intervention in patients with "asymptomatic AMR."


'/>"/>

Contact: Elsevier Newsroom
newsroom@elsevier.com
31-204-853-564
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. ISHLT issues new guidelines for care of mechanical circulatory support device patients
2. Research shows efficacy of treatment model developed at Women & Infants
3. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
4. Vendors in Nevada, Michigan, & Illinois to be Featured on the PartyPOP.com Online Network
5. Beef & Pork Wholesaling in the US Industry Market Research Report Now Available from IBISWorld
6. The Tennessee Car Accident Lawyers at Michael D. Ponce & Associates Alert Public of CDC Survey Revealing Majority of High School Seniors Admitting to Texting Behind Wheel
7. Alex Galindo, Attorney and Partner at Curd, Galindo & Smith, LLP, Court Wins Against the County of Riverside's Motion to Dismiss Medical Malpractice Case
8. Play & Park Structures Included in New Play for All Abilities Playground
9. Gum Disease, HPV May Play Role in Head & Neck Cancers
10. New Treatments Emerging from Immune and Inflammatory Disease R&D Pipelines
11. Version 2.0 of Award-Winning Proloquo2Go App for iPhone, iPad & iPod touch Speeds Up Communication, Adds New Voices and Customization Options
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2020)... , ... May 15, 2020 , ... For patients who have gone to see ... that the office has always had in place. After being allowed to re-open during the ... that patients and staff are as safe and comfortable as possible while going through their ...
(Date:5/15/2020)... ... May 15, 2020 , ... Collagen has taken the ... natural channel alone in 2019, according to a 2020 Nutritional Outlook ‘Ingredients to Watch’ ... further and further away from the high molecular weight, low-impact products of the past ...
(Date:5/15/2020)... PHOENIX (PRWEB) , ... May 15, 2020 , ... How ... question remains unanswered. Thousands of private practice offices are not set up to see ... lack of patient and disease history are challenging to overcome. Doctors and patients need ...
(Date:5/14/2020)... ... May 13, 2020 , ... The Long Island-based ... Developmental Disabilities. , The vision of the Center for Developmental Disabilities is to ... values are embraced: Everyone is treated with dignity and respect. Individual strengths and ...
(Date:5/11/2020)... ... May 11, 2020 , ... PathologyWatch announced today a $5M ... Capital with additional funding by individual investors. PathologyWatch is emerging as the ... process while reducing costs to clinics and enhancing patient care. , ...
Breaking Medicine News(10 mins):
(Date:5/16/2020)... FREEDOM, Pa. (PRWEB) , ... May 16, 2020 , ... ... has developed a low-cost proning cushion to help patients lay face down for extended ... providing proning devices for over 15 years to PTs and Pain Management professionals. We ...
(Date:5/14/2020)... ... May 14, 2020 , ... A new study from the National Alliance ... United States increased by 9.5 million from 2015 to 2020 and now encompasses more ... family caregivers are in worse health compared to five years ago. As the demand ...
(Date:5/14/2020)... ... ... Clear Labs , providers of the only automated and intelligent diagnostic ... by Redmile Group, as well as existing investors including Wing VC, Menlo Ventures, Tyson ... raised $62M. , In addition to supporting ongoing commercialization of the company’s food ...
Breaking Medicine Technology: